{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:11:39Z","timestamp":1778631099104,"version":"3.51.4"},"reference-count":100,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.blre.2012.05.001","type":"journal-article","created":{"date-parts":[[2012,6,13]],"date-time":"2012-06-13T06:46:28Z","timestamp":1339569988000},"page":"183-187","source":"Crossref","is-referenced-by-count":18,"title":["Thrombotic complications associated with stem cell transplantation"],"prefix":"10.1016","volume":"26","author":[{"given":"Yona","family":"Nadir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2012.05.001_bb0005","first-page":"E4","article-title":"Drug-related thrombosis in hematologic malignancies","volume":"8","author":"Nadir","year":"2004","journal-title":"Rev Clin Exp Hematol"},{"key":"10.1016\/j.blre.2012.05.001_bb0010","first-page":"37","article-title":"Pneumopathies of the graft-versus-host reaction. Alveolitis associated with an increased level of tumor necrosis factor mRNA and chronic interstitial pneumonitis","volume":"61","author":"Piguet","year":"1989","journal-title":"Lab Invest"},{"key":"10.1016\/j.blre.2012.05.001_bb0015","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/hep.1840040121","article-title":"Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors","volume":"4","author":"McDonald","year":"1984","journal-title":"Hepatology"},{"key":"10.1016\/j.blre.2012.05.001_bb0020","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood.V85.11.3005.bloodjournal85113005","article-title":"The syndrome of hepatic veno-occlusive disease after marrow transplantation","volume":"85","author":"Bearman","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.blre.2012.05.001_bb0025","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1046\/j.1365-2141.1999.01680.x","article-title":"The pathology, diagnosis, and treatment of hepatic veno-occlusive disease: current status and novel approaches","volume":"107","author":"Richardson","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2012.05.001_bb0030","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000046590","article-title":"Hepatic veno-occlusive disease following hematopoietic stem cell transplantation","volume":"106","author":"Richardson","year":"2001","journal-title":"Acta Haematol"},{"key":"10.1016\/j.blre.2012.05.001_bb0035","first-page":"3599","volume":"92","author":"Carreras","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.blre.2012.05.001_bb0040","doi-asserted-by":"crossref","first-page":"255","DOI":"10.7326\/0003-4819-118-4-199302150-00003","article-title":"Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients","volume":"118","author":"McDonald","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.blre.2012.05.001_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-5926-1-1","article-title":"Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review","volume":"1","author":"Braet","year":"2002","journal-title":"Comp Hepatol"},{"key":"10.1016\/j.blre.2012.05.001_bb0050","doi-asserted-by":"crossref","first-page":"G1045","DOI":"10.1152\/ajpgi.00526.2002","article-title":"Embolization by sinusoidal lining cells obstructs the microcirculation in rat sinusoidal obstruction syndrome","volume":"284","author":"DeLeve","year":"2003","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.blre.2012.05.001_bb0055","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1200\/JCO.1993.11.9.1729","article-title":"Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation","volume":"11","author":"Bearman","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2012.05.001_bb0060","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1055\/s-2002-23204","article-title":"Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease)","volume":"22","author":"DeLeve","year":"2002","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.blre.2012.05.001_bb0065","first-page":"549","article-title":"Hepatic veno-occlusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occluded central venules","volume":"127","author":"Shulman","year":"1987","journal-title":"Am J Pathol"},{"key":"10.1016\/j.blre.2012.05.001_bb0070","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/hep.1840190515","article-title":"Veno-occlusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms","volume":"19","author":"Shulman","year":"1994","journal-title":"Hepatology"},{"key":"10.1016\/j.blre.2012.05.001_bb0075","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/hep.510240414","article-title":"Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation","volume":"24","author":"DeLeve","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.blre.2012.05.001_bb0080","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/sj.bmt.1702377","article-title":"The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity","volume":"25","author":"Hassan","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2012.05.001_bb0085","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/sj.bjc.6603097","article-title":"High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy","volume":"94","author":"de Jonge","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.blre.2012.05.001_bb0090","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/hep.1840060322","article-title":"Sublobular distribution of transferases and hydrolases associated with glucuronide, sulfate and glutathione conjugation in human liver","volume":"6","author":"el Mouelhi","year":"1986","journal-title":"Hepatology"},{"key":"10.1016\/j.blre.2012.05.001_bb0095","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0022-3565(25)38620-9","article-title":"Dacarbazine toxicity in murine liver cells: a model of hepatic endothelial injury and glutathione defense","volume":"268","author":"Deleve","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.blre.2012.05.001_bb0100","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1002\/1097-0142(19881001)62:7<1275::AID-CNCR2820620705>3.0.CO;2-I","article-title":"Glutathione monoethyl ester can selectively protect liver from high dose BCNU or cyclophosphamide","volume":"62","author":"Teicher","year":"1988","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2012.05.001_bb0105","first-page":"747","article-title":"Parameters of the fibrinolytic system in patients undergoing BMT: elevation of PAI-1 in veno-occlusive disease","volume":"14","author":"Salat","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2012.05.001_bb0110","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s002770050364","article-title":"Endothelial dysfunction after bone marrow transplantation: increase of soluble thrombomodulin and PAI-1 in patients with multiple transplant-related complications","volume":"76","author":"Nurnberger","year":"1998","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2012.05.001_bb0115","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.thromres.2004.12.010","article-title":"Transforming growth factor beta-1 released from platelets contributes to hypercoagulability in veno-occlusive disease following hematopoetic stem cell transplantation","volume":"116","author":"Pihusch","year":"2005","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2012.05.001_bb0120","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1056\/NEJM199306033282203","article-title":"Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer","volume":"328","author":"Anscher","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2012.05.001_bb0125","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/0049-3848(91)90176-W","article-title":"Liver veno-occlusive disease after bone marrow transplantation changes in coagulation parameters and endothelial markers","volume":"63","author":"Scrobohaci","year":"1991","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2012.05.001_bb0130","first-page":"1082","article-title":"IL-6 and IL-8 levels in plasma during hematopoietic progenitor transplantation","volume":"83","author":"Ferra","year":"1998","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2012.05.001_bb0135","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/sj.bmt.1701952","article-title":"The prothrombin gene variant G20210A but not factor V leiden may be associated with veno-occlusive disease following BMT","volume":"24","author":"Duggan","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2012.05.001_bb0140","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1038\/sj.bmt.1702390","article-title":"Factor V Leiden mutation as a predisposing factor for veno-occlusive disease following BMT","volume":"25","author":"Ertem","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2012.05.001_bb0145","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1756-8722-3-36","article-title":"Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia","volume":"3","author":"Pidala","year":"2010","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.blre.2012.05.001_bb0150","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/(SICI)1096-8652(200005)64:1<32::AID-AJH6>3.0.CO;2-N","article-title":"The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation","volume":"64","author":"Ohashi","year":"2000","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2012.05.001_bb0155","first-page":"367","article-title":"Pilot trial of prophylactic ursodiol to decrease the incidence of veno-occlusive disease of the liver in allogeneic bone marrow transplant patients","volume":"10","author":"Essell","year":"1992","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2012.05.001_bb0160","doi-asserted-by":"crossref","first-page":"975","DOI":"10.7326\/0003-4819-128-12_Part_1-199806150-00002","article-title":"Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial","volume":"128","author":"Essell","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.blre.2012.05.001_bb0165","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1182\/blood-2001-12-0159","article-title":"Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation","volume":"100","author":"Ruutu","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.blre.2012.05.001_bb0170","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1182\/blood.V79.11.2834.bloodjournal79112834","article-title":"Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial","volume":"79","author":"Attal","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.blre.2012.05.001_bb0175","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1097\/00007890-199604150-00014","article-title":"Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients","volume":"61","author":"Or","year":"1996","journal-title":"Transplantation"},{"key":"10.1016\/j.blre.2012.05.001_bb0180","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/sj.bmt.1702854","article-title":"Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecular weight heparin","volume":"27","author":"Simon","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2012.05.001_bb0185","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/sj.bmt.1703342","article-title":"A randomized trial of heparin plus ursodiol vs. heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation","volume":"29","author":"Park","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2012.05.001_bb0190","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1038\/sj.bmt.1704087","article-title":"Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study","volume":"31","author":"Forrest","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2012.05.001_bb0195","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3109\/10428199809059219","article-title":"Prevention and treatment of hepatic venocclusive disease after high-dose cytoreductive therapy","volume":"31","author":"Richardson","year":"1998","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2012.05.001_bb0200","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood.V89.5.1501","article-title":"Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients","volume":"89","author":"Bearman","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.blre.2012.05.001_bb0205","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/sj.bmt.1703881","article-title":"Recombinant tissue plasminogen activator for treatment of hepatic veno-occlusive disease following bone marrow transplantation in children: effectiveness and a scoring system for initiating treatment","volume":"31","author":"Bajwa","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2012.05.001_bb0210","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1182\/blood-2003-01-0255","article-title":"Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation","volume":"102","author":"Wadleigh","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2012.05.001_bb0215","first-page":"737","article-title":"Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population","volume":"92","author":"Richardson","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.blre.2012.05.001_bb0220","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1046\/j.1365-2141.2000.02475.x","article-title":"Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study","volume":"111","author":"Chopra","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2012.05.001_bb0225","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/sj.bmt.1701650","article-title":"Defibrotide as salvage therapy for refractory veno-occlusive disease of the liver complicating allogeneic bone marrow transplantation","volume":"23","author":"Abecasis","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2012.05.001_bb0230","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/BF00609244","article-title":"Acute effects of defibrotide, an experimental antithrombotic agent, on fibrinolysis and blood prostanoids in man","volume":"35","author":"Coccheri","year":"1988","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.blre.2012.05.001_bb0235","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0090-6980(90)90099-H","article-title":"Defibrotide, by enhancing prostacyclin generation, prevents endothelin-1 induced contraction in human saphenous veins","volume":"40","author":"Berti","year":"1990","journal-title":"Prostaglandins"},{"key":"10.1016\/j.blre.2012.05.001_bb0240","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1055\/s-0038-1642468","article-title":"Defibrotide stimulates expression of thrombomodulin in human endothelial cells","volume":"71","author":"Zhou","year":"1994","journal-title":"Thromb Haemost"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2012.05.001_bb0245","first-page":"186","article-title":"Antithrombotic effect and clinical potential of defibrotide","volume":"19","author":"Ulutin","year":"1993","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.blre.2012.05.001_bb0250","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/00003495-199345020-00007","article-title":"Defibrotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders","volume":"45","author":"Palmer","year":"1993","journal-title":"Drugs"},{"key":"10.1016\/j.blre.2012.05.001_bb0255","first-page":"6","article-title":"Defibrotide: an endothelium protecting and stabilizing drug, has an anti-angiogenic potential in vitro and in vivo","author":"Koehl","year":"2007","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.blre.2012.05.001_bb0260","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/sj.leu.2403004","article-title":"Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells","volume":"17","author":"Falanga","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2012.05.001_bb0265","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1182\/blood-2002-04-1216","article-title":"Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome","volume":"100","author":"Richardson","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.blre.2012.05.001_bb0270","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.bbmt.2010.02.009","article-title":"Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial","volume":"16","author":"Richardson","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2012.05.001_bb0275","first-page":"795","article-title":"Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of pre-emptive antithrombin III replacement and combined antithrombin III\/defibrotide therapy","volume":"91","author":"Haussmann","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2012.05.001_bb0280","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.bmt.1705696","article-title":"Prophylactic defibrotide in allogeneic stem cell transplantation: minimal morbidity and zero mortality from veno-occlusive disease","volume":"40","author":"Dignan","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2012.05.001_bb0285","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/j.1365-2141.2009.07871.x","article-title":"Absence of VOD in paediatric thalassaemic HSCT recipients using defibrotide prophylaxis and intravenous Busulphan","volume":"147","author":"Cappelli","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2012.05.001_bb0290","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1097\/00007890-200211150-00018","article-title":"Hemostatic complications in bone marrow transplantation: a retrospective analysis of 447 patients","volume":"74","author":"Pihusch","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.blre.2012.05.001_bb0295","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/sj.bmt.1701830","article-title":"Severe thrombotic microangiopathy: an infrequent complication of bone marrow transplantation. Gruppo Italiano Trapianto Midollo Osseo (GITMO)","volume":"24","author":"Iacopino","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2012.05.001_bb0300","doi-asserted-by":"crossref","first-page":"421","DOI":"10.4065\/78.4.421","article-title":"Posttransplantation thrombotic thrombocytopenic purpura: a single-center experience and a contemporary review","volume":"78","author":"Elliott","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.blre.2012.05.001_bb0305","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/sj.bmt.1705758","article-title":"Diagnosis and treatment of transplantation-associated thrombotic microangiopathy: real progress or are we still waiting?","volume":"40","author":"Batts","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2012.05.001_bb0310","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/sj.bmt.1703710","article-title":"Transplantation-associated thrombotic microangiopathy: twenty-two years later","volume":"30","author":"Daly","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2012.05.001_bb0315","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/sj.bmt.1705599","article-title":"Acute renal failure after allogeneic myeloablative stem cell transplantation: retrospective analysis of incidence, risk factors and survival","volume":"39","author":"Kersting","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2012.05.001_bb0320","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/sj.bmt.1705160","article-title":"Transplant-associated microangiopathy (TAM) in recipients of allogeneic hematopoietic stem cell transplants","volume":"36","author":"Martinez","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2012.05.001_bb0325","first-page":"495","article-title":"Thrombotic microangiopathy following bone marrow transplantation","volume":"14","author":"Pettitt","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2012.05.001_bb0330","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/sj.bmt.1701047","article-title":"Severe cerebellar swelling and thrombotic thrombocytopenic purpura associated with FK506","volume":"21","author":"Tezcan","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2012.05.001_bb0335","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/sj.bmt.1705976","article-title":"Clinical impact of thrombotic microangiopathy on the outcome of patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation","volume":"41","author":"Cho","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2012.05.001_bb0340","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0925-5710(95)00431-9","article-title":"Cyclosporine-related encephalopathy following allogeneic bone marrow transplantation","volume":"63","author":"Teshima","year":"1996","journal-title":"Int J Hematol"},{"key":"10.1016\/j.blre.2012.05.001_bb0345","first-page":"455","article-title":"Cyclosporin-induced endothelial cell injury","volume":"55","author":"Zoja","year":"1986","journal-title":"Lab Invest"},{"key":"10.1016\/j.blre.2012.05.001_bb0350","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1097\/00007890-199006000-00038","article-title":"Severe endothelial injury in a renal transplant patient receiving cyclosporine","volume":"49","author":"Fogo","year":"1990","journal-title":"Transplantation"},{"key":"10.1016\/j.blre.2012.05.001_bb0355","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1097\/00007890-199911150-00020","article-title":"Microangiopathy in kidney and simultaneous pancreas\/kidney recipients treated with tacrolimus: evidence of endothelin and cytokine involvement","volume":"68","author":"Burke","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.blre.2012.05.001_bb0360","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/ajh.20648","article-title":"Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation","volume":"81","author":"Nakamae","year":"2006","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2012.05.001_bb0365","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/sj.bmt.1703414","article-title":"Defibrotide as a promising treatment for thrombotic thrombocytopenic purpura in patients undergoing bone marrow transplantation","volume":"29","author":"Corti","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2012.05.001_bb0370","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/sj.bmt.1702441","article-title":"Prompt response to high-dose intravenous immunoglobulins given as first-line therapy in post-transplant thrombotic thrombocytopenic purpura","volume":"25","author":"Alessandrino","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2012.05.001_bb0375","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1053\/bbmt.2001.v7.pm11349809","article-title":"Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation","volume":"7","author":"Ho","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2012.05.001_bb0380","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0002-9343(94)90062-0","article-title":"Corticosteroids as adjunctive therapy for diffuse alveolar hemorrhage associated with bone marrow transplantation. University of Nebraska Medical Center Bone Marrow Transplant Group","volume":"96","author":"Metcalf","year":"1994","journal-title":"Am J Med"},{"key":"10.1016\/j.blre.2012.05.001_bb0385","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/sj.bmt.1701173","article-title":"High-dose cyclophosphamide, etoposide and carboplatin with autologous bone marrow support for metastatic breast cancer: long-term results","volume":"21","author":"Baker","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2012.05.001_bb0390","doi-asserted-by":"crossref","first-page":"145","DOI":"10.7326\/0003-4819-114-2-145","article-title":"Corticosteroid therapy for diffuse alveolar hemorrhage in autologous bone marrow transplant recipients","volume":"114","author":"Chao","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.blre.2012.05.001_bb0395","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1053\/bbmt.2001.v7.pm11215699","article-title":"High-dose therapy and autologous hematopoietic cell transplantation in children with primary refractory and relapsed Hodgkin's disease: atopy predicts idiopathic diffuse lung injury syndromes","volume":"7","author":"Frankovich","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2012.05.001_bb0400","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.bbmt.2006.06.002","article-title":"Diffuse alveolar hemorrhage and infection-associated alveolar hemorrhage following hematopoietic stem cell transplantation: related and high-risk clinical syndromes","volume":"12","author":"Majhail","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2012.05.001_bb0405","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/sj.bmt.1705521","article-title":"Alveolar hemorrhage following allogeneic hematopoietic cell transplantation using reduced-intensity conditioning","volume":"38","author":"Majhail","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2012.05.001_bb0410","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1164\/ajrccm\/146.2.485","article-title":"Pulmonary complications in lymphoma patients treated with high-dose therapy autologous bone marrow transplantation","volume":"146","author":"Jules-Elysee","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.blre.2012.05.001_bb0415","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0002-9343(89)80606-0","article-title":"Diffuse alveolar hemorrhage in autologous bone marrow transplant recipients","volume":"87","author":"Robbins","year":"1989","journal-title":"Am J Med"},{"key":"10.1016\/j.blre.2012.05.001_bb0420","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1136\/jcp.36.5.546","article-title":"Histopathology of the lung after bone marrow transplantation","volume":"36","author":"Sloane","year":"1983","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.blre.2012.05.001_bb0425","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/00007890-199401000-00016","article-title":"Pulmonary hemorrhage as a cause of death in allogeneic bone marrow recipients with severe acute graft-versus-host disease","volume":"57","author":"Wojno","year":"1994","journal-title":"Transplantation"},{"key":"10.1016\/j.blre.2012.05.001_bb0430","first-page":"3025","article-title":"Immune-related injury to endothelium associated with acute graft-versus-host disease in the rat","volume":"21","author":"Beschorner","year":"1989","journal-title":"Transplant Proc"},{"key":"10.1016\/j.blre.2012.05.001_bb0435","first-page":"301","article-title":"Diffuse alveolar hemorrhage following autologous bone marrow infusion","volume":"12","author":"Corso","year":"1993","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2012.05.001_bb0440","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/0002-9343(91)80180-T","article-title":"Diffuse alveolar hemorrhage in autologous bone marrow transplant recipients","volume":"90","author":"Mulder","year":"1991","journal-title":"Am J Med"},{"key":"10.1016\/j.blre.2012.05.001_bb0445","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/00024382-200014010-00008","article-title":"Distinct effects of systemic infusion of G-CSF vs. IL-6 on lung and liver inflammation and injury in hemorrhagic shock","volume":"14","author":"Meng","year":"2000","journal-title":"Shock"},{"key":"10.1016\/j.blre.2012.05.001_bb0450","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00003246-200001000-00042","article-title":"Use of high-dose corticosteroids and high-frequency oscillatory ventilation for treatment of a child with diffuse alveolar hemorrhage after bone marrow transplantation: case report and review of the literature","volume":"28","author":"Haselton","year":"2000","journal-title":"Crit Care Med"},{"key":"10.1016\/j.blre.2012.05.001_bb0455","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/sj.mn.7300151","article-title":"Mechanisms of leukocyte sequestration in inflamed lungs","volume":"8","author":"Doerschuk","year":"2001","journal-title":"Microcirculation"},{"key":"10.1016\/j.blre.2012.05.001_bb0460","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/sj.bmt.1701995","article-title":"High-dose corticosteroid therapy for diffuse alveolar hemorrhage in allogeneic bone marrow stem cell transplant recipients","volume":"24","author":"Raptis","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2012.05.001_bb0465","first-page":"863","article-title":"Diffuse alveolar haemorrhage associated with microangiopathy after allogeneic bone marrow transplantation","volume":"15","author":"Srivastava","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2012.05.001_bb0470","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/sj.bmt.1703157","article-title":"Off-label use of recombinant factor VIIa in patients following bone marrow transplantation","volume":"28","author":"Blatt","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2012.05.001_bb0475","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/107602960501100406","article-title":"Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated factor VII","volume":"11","author":"Brenner","year":"2005","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.blre.2012.05.001_bb0480","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/j.1538-7836.2005.01523.x","article-title":"Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation","volume":"3","author":"Pihusch","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2012.05.001_bb0485","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.rmed.2009.02.004","article-title":"Pulmonary hemorrhage: a novel mode of therapy","volume":"103","author":"Solomonov","year":"2009","journal-title":"Respir Med"},{"key":"10.1016\/j.blre.2012.05.001_bb0490","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1096\/fj.10-162040","article-title":"Efficient nonadhesive ex vivo expansion of early endothelial progenitor cells derived from CD34+ human cord blood fraction for effective therapeutic vascularization","volume":"25","author":"O E","year":"2011","journal-title":"FASEB J"},{"key":"10.1016\/j.blre.2012.05.001_bb0495","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1161\/CIRCULATIONAHA.111.048264","article-title":"Multipotent vasculogenic pericytes from human pluripotent stem cells promote recovery of murine ischemic limb","volume":"125","author":"Dar","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.blre.2012.05.001_bb0500","doi-asserted-by":"crossref","first-page":"58","DOI":"10.2353\/ajpath.2010.091008","article-title":"PDGF-C mediates glomerular capillary repair","volume":"177","author":"Boor","year":"2011","journal-title":"Am J Pathol"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X12000434?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X12000434?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T03:19:32Z","timestamp":1743391172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X12000434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":100,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0268960X12000434"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2012.05.001","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}